Jon Masters Email & Phone Number

Lawrence Township, NJ, US

Boston, Massachusetts, US

Watertown, Massachusetts, US

• Selected as member of three-person team to lead full integration of Forma Therapeutics into Novo Nordisk A/S.
• Provide oversight of creation and execution of transition plans for business and R&D functions ensuring progress while not impacting critical R&D development advances.
• Assist broader transition team to identify, triage and address daily challenges as they arise.
• Lead procurement integration from legacy Forma side; ensuring transition to end state and ongoing support; lead winddown of certain legacy programs; lead ongoing forecasting & budgeting.
• Support successful efforts to out-license two oncology programs: USP1 inhibitor FT-3171 to Debiopharm and CBP/p300 inhibitor FT-7051 to Pathos.

Watertown, Massachusetts, US

Watertown, Massachusetts, US

• Capital Raising & Business Development
• Member of five-person leadership team (including CEO, CFO, GC, Head BD) assessing and leading activities culminating in $1.1 billion acquisition of company by Novo Nordisk.
• Supported financing efforts including $100 million Series D Private Equity financing, $319 million Initial Public Offering and S-1 preparations, and $276 million Follow-on offering.
• Provided financial and analytical support for process culminating in license of NDA-filed drug candidate, Olutasidenib, to Rigel Pharmaceuticals.Strategic Finance
• Conducted ad-hoc analyses supporting scenario planning, valuation, portfolio optimization, resource planning, financing, and business alternatives such as divestiture or partnerships.
• Supported evolution of company from research and early development to late development and commercial-planning focus.

Durham, NC, US

• Led company-wide long-range strategic planning process. Created Idera’s first long-range plan.
• Conducted strategic financial analysis to support portfolio prioritization, scenario planning, funding assessments, and business development for Leadership Team and Board of Directors.
• Led annual budget and quarterly refresh processes. Created Idera’s first detailed budget.
• Managed insurance coverage including P&C, clinical trial liability, executive risk and D&O.

Cambridge, MA, US

• Engaged in daily interaction with Wall Street, including communicating corporate strategy and performance to analysts and investors.
• Led communication around commercial message including drafting earnings script and conference presentations for EVP of Commercial; supported overall earnings calls and conference preparation.
• Assessed sell-side analyst financial models to identify errors and areas in need of guidance; monitored sell-side analyst reports for competitive and market intelligence.
• Provided regular updates to executive leadership about the company's stock price, analysts' estimates, investor perceptions, competitive intelligence, and peer company performance.
• Coordinated corporate communication efforts with Public Affairs department, ensuring a consistent message was provided to external constituents.

Cambridge, MA, US

• Led team of over 20 employees in Reporting & Analytics, Compliance, Knowledge Management, Leadership Development, Operational Effectiveness, Quality and Training.
• Restructured team to prepare for new product launches; created new Operational Effectiveness team to drive department optimization, efficiency and flexibility; centralized Quality monitoring functions to best address.

Cambridge, MA, US

• Formed, expanded and led team of eight employees and six part-time contractors/interns to support operational and strategic analysis and report needs of department as well as requests from the Board of Directors.
• Systematically leveraged data from over one million annual patient and healthcare provider calls to identify revenue and cost savings opportunities.
• Restructured reporting infrastructure to prepare for launch of new drugs in new therapeutic areas; lead annual goal process, business plan creation and tracking, contest creation and tracking.
• Led company-wide efforts to understand and monitor Drug Holidays; helped drive enhancements to patient financial assistance including $10 CoPay and infusion cost assistance programs.
• Led team to complete over 1,500 projects including management and operational dashboards, ROI and benefit analyses and partner management reports.

Cambridge, MA, US

• Led Discovery & Development 2009 budget and long-range plan processes for ~$600 million function including supporting expenditure and headcount target-setting process, guiding functions toward targets, preparing.
• Supported immunology and cardiovascular development programs as financial lead including managing program budgets and performing ad hoc analyses to evaluate life cycle initiatives, portfolio mix and new drug.
• Managed financial aspects of development collaboration with Cardiokine; standardized and automated quarterly reporting; resolved and negotiated ad-hoc collaboration financial issues; managed budget.
• Created and maintained cardiovascular therapeutic-area discounted cash flow model to analyze development and commercial scenarios, funding arrangements and new product acquisitions.
• Managed immunology/cardiovascular discovery biology and medical research budgets.

Cambridge, MA, US

• Coordinated with business units (commercial, clinical, research, manufacturing) and outside consultants to develop opportunity-specific operating and valuation models to evaluate licensing, partnering, acquisition.
• Supported term sheet and contract negotiation and document drafting; provided initial tax and accounting guidance and coordinate with corresponding departments in complex situations.
• Prepared and presented financial analysis and implications of opportunities to the Chief Financial Officer and Executive Committee; supported presentations to the Board of Directors.
• Provided ad-hoc support for venture capital, research-stage and intellectual property transactions.
• Performed strategic and benchmarking analysis for the Chief Financial Officer; supported special projects and corporate sale exploration process.
• Created and maintained models to forecast royalty and investment income, diluted shares and tax rate.

New York City, New York, US

• Developed and reviewed merger, discounted cash flow, financing and business case financial models; led surveys and analysis of market segments.
• For “buy-side” clients, identified and approached acquisition targets and participated in due diligence; for “sell-side” clients, identified and marketed clients to potential acquirers, prepared clients for and.
• Managed teams of one to three analysts on all new business presentations and client engagements; actively involved in pitching for new business.
• Completed five transactions totaling over $600 million including a cross-border public acquisition, a cross-border sale, a public company sale, an initial public offering and a follow-on offering.

Jersey City, NJ, US

• Industry owned utility that annually processes $900 trillion of securities transactions.
• Managed financial analysis and reporting responsibility for $250 million revenue division; improved monthly reporting process, increasing relevance while reducing labor involved.
• Performed analyses and developed financial models for new services and pricing scenarios; analyzed macroeconomic trends and business drivers to improve forecasting accuracy.

Boston, Massachusetts, US

• Venture capital firm managing $2 billion focused on media, telecommunications and service industries.
• Sourced investment opportunities by conducting targeted market research, contacting private company CEOs, attending industry conferences, meeting with investment bankers.
• Reviewed and evaluated over 200 potential investment opportunities; conducted financial, operational and managerial due diligence; performed competitive analysis and financial modeling; presented assessment of.
• Led due diligence for investment in educational institution; developed primary relationship with management and led investment process for advertising firm.
• Managed portfolio companies including assisting two distressed companies, presenting financial model to investors and lenders as part of a $500 million fundraising process and directing market opportunity analysis.

New York, NY, US

• Developed financial models to evaluate impact of M&A transactions, debt and equity financings; valued firms using discounted cash flow, comparable company and recent transaction analysis.
• Prepared management, Board of Directors and roadshow presentations; represented firm during roadshow marketing presentations; conducted and facilitated due diligence.
• Completed three advisory assignments valued at over $1.5 billion and five equity financings raising over $4 billion.

Mba, Business (Concentrations In Finance, Accounting, Management & Strategy, Decision Science)

Ba, Economics

Education record